FREMONT, Calif., Feb. 22 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc.
(PDL) (Nasdaq: PDLI) today announced that its financial results for the fourth
quarter and year ended December 31, 2005 will be released following the close
of the U.S. financial markets on Monday, February 27, 2006. PDL will hold a
conference call to discuss these financial results, its commercial and
clinical activities and its forward-looking information and guidance with
respect to future results at 4:30 p.m. Eastern time on February 27, 2006. The
call will be hosted by Mr. Mark McDade, Chief Executive Officer, and
Dr. Steven Benner, Senior Vice President and Chief Medical Officer.
The live webcast will be available through the PDL website: http://www.pdl.com.
Please connect to this website at least 15 minutes prior to the live webcast
to allow time for any software download that may be needed to hear the
webcast. Financial and statistical information to be discussed in the call
will be available on the PDL website immediately prior to the commencement of
the call. A replay will be available at http://www.pdl.com starting approximately one
hour after completion of the webcast.
An audio replay will also be available by telephone from approximately
6:30 p.m. Eastern time on February 27, 2006 through 6:30 p.m. Eastern time on
March 3, 2006. To access the replay, dial 800-633-8284 from inside the United
States and 402-977-9140 from outside the United States; enter conference ID
number 21284399.
PDL BioPharma, Inc. is a biopharmaceutical company focused on discovering,
developing and commercializing innovative therapies for severe or life
threatening illnesses. The company currently markets and sells a portfolio of
leading products in the acute-care hospital setting in the United States and
Canada and generates royalties through licensing agreements with top-tier
biotechnology and pharmaceutical companies based on its pioneering humanized
antibody technology. Currently, PDL BioPharma's diverse late-stage product
pipeline includes six investigational compounds in Phase 2 or Phase 3 clinical
development for hepatorenal syndrome, inflammation and autoimmune diseases,
cardiovascular disorders and cancer. For more information, please see our
website at http://www.pdl.com.
NOTE: PDL BioPharma and the PDL logo are considered trademarks of PDL
BioPharma, Inc.
SOURCE PDL BioPharma, Inc.
 back to top
Related links:
http://www.pdl.com
CONTACT:
Ami Knoefler, Senior Director, Corporate and
Investor Relations, +1-510-284-8851, or ami.knoefler@pdl.com, or
James R. Goff, Senior Director, Investor Relations,
+1-510-574-1421, or james.goff@pdl.com, both of PDL BioPharma,
Inc.
|
